Bone Disorders
An Introduction to Bone Disorders
Osteoporosis medications aim to markedly reduce the occurrence of fractures but can have rare and serious adverse effects. The introduction of new drug classes, including an anti-sclerostin monoclonal antibody and a parathyroid hormone-related peptide analogue, into the treatment landscape, offers new options to patients. The potential for cell-based therapies and drugs that target the elimination of senescent cells in the bone microenvironment are currently being investigated.
Browse our gallery of video highlights and short articles from the conference hub, providing the latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Meet the endocrinologists shaping the future of the specialty. The touchENDOCRINOLOGY Future Leaders 2026 are rising stars nominated by the endocrinology community for their contributions to research, clinical practice and innovation. Discover the clinicians and researchers challenging convention, advancing care and driving progress across endocrinology.
We are delighted to announce Dr Rimesh Pal as a touchENDOCRINOLOGY Future Leader 2026, recognized by his peers as an emerging leader in endocrinology and metabolic bone research. Dr Rimesh Pal is Associate Professor of Endocrinology at the Postgraduate Institute of ...
New data presented at ENDO 2026 highlighted the continued evolution of endocrine care, with studies spanning rare disease management, long-term hormone replacement, artificial intelligence-supported screening and real-world treatment outcomes. Across several presentations, investigators reported sustained improvements in biochemical, metabolic, skeletal and patient-reported outcomes, while also emphasising the importance of long-term follow-up and careful interpretation of emerging data.
Welcome to the summer 2026 issue of touchREVIEWS in Endocrinology. In this issue, we bring together articles that reflect the evolving complexity of endocrine and metabolic disease, while highlighting the growing importance of patient-centred care, translational science and interdisciplinary management. We ...
The significance of osteoporosis and fragility fractures in individuals with chronic kidney disease (CKD) is becoming increasingly recognized as a major contributor to disability, hospital admissions and mortality. In CKD, bone fragility is worsened by the complex interactions of metabolic ...
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
Rare diseases can present numerous challenges for those living with these conditions and the healthcare professionals caring for them. In this interview we discuss some of these with Lisa Sarfaty, VP of Communication and Engagement for NORD (The National Organization ...
Our society partner, NORD (The National Organization for Rare Disorder) has planned several initiatives to support this year’s Rare Disease Day on 28 February. These activities are aimed at raising awareness about rare diseases and the challenges faced by people ...
It was a pleasure to talk with Dr. Andrea R Genazzani (International Society of Gynecological Endocrinology and European Society of Gynecology) to find out when, in whom and for how long hormone replacement therapy should be administered for bone loss ...
touchENDOCRINOLOGY were delighted to catch up with Dr. Andrea R. Genazzani (International Society of Gynecological Endocrinology and European Society of Gynecology) to discuss the health burden of osteoporosis in post-menopausal women and how HRT could be used as a prevention ...
We were delighted to talk with Dr Michael R. McClung (Oregon Osteoporosis Center, Portland, OR, USA) around the current unmet needs and standard of care for osteoporosis and the therapeutic targets currently being investigated that could lead to new drug ...
Dr Richard Keen (Director, Centre for Metabolic Bone Disease, Royal National Orthopaedic Hospital, Stanmore, UK) joins us for Rare Disease Day to discuss the spectrum of rare bone disorders, the challenges of diagnosis, and the impact on patient quality of ...
Ethan Crough, a middle school technology education teacher, joins us for Rare Disease Day to celebrate diversity as a man living with achondroplasia. Ethan discusses his experiences of living with achondroplasia and highlights useful resources such as Little People of ...
touchIMMUNOLOGY joins Professor Nicola Veronese (University of Padova, Italy) at WCO21 to discuss the efficacy, safety and quality of pharma-grade chondroitin sulfate in osteoarthritis treatment. Questions 1. What is the rationale for the use of highly purified chondroitin sulfate (hpCS) in ...
touchIMMUNOLOGY joins Professor Neil Gittoes (University of Birmingham, UK), Chair of the Royal Osteoporosis Society, at WCO21 to discuss the mission of the society and hopes for the current initiatives to forward osteoporosis research. Questions 1. Could you tell us a ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
